[Disclosure] Celltrion (068270) Submits Application for Domestic Marketing Authorization of ‘CT-P6 SC’ (Herzuma Subcutaneous Formulation)

Fact Source: Financial Supervisory Service DART / 2026-05-28

Disclosure Type: Major Management Event Related to Investment Judgement

💡 3-Second Summary

Celltrion has officially applied for marketing authorization to the South Korean Ministry of Food and Drug Safety (MFDS) for CT-P6 SC, the subcutaneous formulation of its breast cancer treatment ‘Herzuma,’ following Phase 1 results demonstrating pharmacokinetic equivalence to the reference product.

📊 1. [Summary of Key Disclosure Content and Figures]

• Product and Formulation Name: CT-P6 SC (Herzuma Subcutaneous Formulation)
• Target Indications (All Approved Indications of Reference Product): Early Breast Cancer, Metastatic Breast Cancer
• Submission Date & Regulatory Authority: May 28, 2026 / Ministry of Food and Drug Safety (MFDS) of South Korea
• Phase 1 Clinical Trial Data Summary (203 Subjects):
  • Pharmacokinetics (PK): In a Phase 1 study comparing the candidate with Herceptin subcutaneous formulation, the 90% confidence intervals for primary endpoints AUC0-inf and Cmax fell completely within the predefined equivalence margin of 80% to 125%, proving PK equivalence.
  • Safety: Treatment-emergent adverse events were reported in 89.5% of total subjects, showing a similar distribution across the comparative groups. Most cases were categorized as mild or moderate, and no treatment-emergent serious adverse events were observed.
  • Immunogenicity: The incidence of ADA/NAb against trastuzumab and rHuPH20 remained generally low and comparable between the two groups, with no clinically meaningful impact on the safety profile.
• Future Operations: Following this domestic regulatory submission in South Korea, the company plans to continuously submit regulatory applications across multiple countries globally.

📈 2. [Professional Insight: What This Disclosure Means for Investors]

• Transition Into the Institutional Review Phase: Moving from clinical evaluations to the regulatory approval process marks a clear operational milestone. Securing the technical application filing in South Korea first serves as a primary pipeline anchor that could streamline subsequent commercialization and multi-regional regulatory timelines.
• Validation of Robust Technical Equivalence: The fact that the primary PK parameters (AUC0-inf and Cmax) settled entirely within the tight statistical boundaries of 80% to 125% demonstrates strong bio-similarity. This stable profile, coupled with a lack of serious safety anomalies, may serve as a positive underlying factor during the regulatory agency’s technical evaluation.
• Persistent Regulatory Review Uncertainty: The submission of a marketing application does not guarantee an eventual approval from the MFDS. The institutional review process may involve requests for supplementary data or administrative bottlenecks that could delay or modify commercial goals. Investors should monitor the regulatory evaluation timeline carefully rather than treating the filing as a definitive final success.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion is advancing its oncology pipeline by converting its established intravenous assets into subcutaneous (SC) formulations to maximize clinical flexibility. The filing with the South Korean MFDS is backed by Phase 1 clinical data from 203 healthy subjects, which confirmed that the core pharmacokinetic parameters, safety metrics, and immunogenicity factors align closely with the reference product. Although submitting a marketing application does not automatically secure an immediate product launch, it successfully shifts the candidate from developer risk into regulatory review risk. Long-term international investors should focus on how smoothly Celltrion secures this domestic validation and how effectively it utilizes these data points for subsequent global roll-outs.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.